Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS), a clinical-stage global biopharmaceutical company focusing on cancer treatments, has announced new employment inducement grants. The Compensation Committee of the company's Board of Directors has granted four new employees options to purchase a total of 24,100 shares of common stock at an exercise price of $17.47 per share, which was the closing price on October 8, 2024. Additionally, these employees received restricted stock units to acquire a total of 12,050 shares of common stock.

These equity awards were granted under the company's 2020 Inducement Plan, which was approved by the Board of Directors in January 2020 in accordance with the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

Positive

• Arcus Biosciences is attracting new talent by offering competitive equity compensation packages
• The company is utilizing its 2020 Inducement Plan to grant stock options and restricted stock units to new employees

Negative

• None.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 24,100 shares of the Company’s common stock at an exercise price per share of $17.47, which was the closing price on October 8, 2024, and restricted stock units to acquire a total of 12,050 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20241009838465/en/

Investor Inquiries:

Pia Eaves

VP of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Source: Arcus Biosciences

FAQ

How many new employees received stock options from Arcus Biosciences (RCUS) in the recent grant?

Arcus Biosciences (RCUS) granted stock options to four new employees in the recent employment inducement grant.

What was the total number of stock options granted by Arcus Biosciences (RCUS) in this announcement?

Arcus Biosciences (RCUS) granted a total of 24,100 stock options to new employees in this announcement.

What was the exercise price for the stock options granted by Arcus Biosciences (RCUS) on October 8, 2024?

The exercise price for the stock options granted by Arcus Biosciences (RCUS) on October 8, 2024, was $17.47 per share.

How many restricted stock units did Arcus Biosciences (RCUS) grant to new employees in this announcement?

Arcus Biosciences (RCUS) granted a total of 12,050 restricted stock units to new employees in this announcement.

Under which plan were the equity awards granted by Arcus Biosciences (RCUS)?

The equity awards were granted under Arcus Biosciences' (RCUS) 2020 Inducement Plan, approved in January 2020.